BRUSSELS, Sept. 30 /PRNewswire/ — People with Parkinson’s
disease who used once-daily Neupro® (rotigotine) in the RECOVER
trial achieved improvements in quality of life, in addition to
previously reported beneficial effects on motor and non-motor
symptoms.
Data presented this week at the 2nd World Parkinson Congress in
Glasgow, UK, showed that Neupro® provided clinically relevant
improvements in PDQ-8 score. This is a self-administered
health-related quality of life questionnaire (HRQL) for Parkinson’s
disease comprising eight items – mobility, activities of
daily living, emotional well-being, social support, cognition,
communication, bodily discomfort and stigma.
“Data from the RECOVER trial demonstrated improvements in motor
and non-motor symptoms for people living with Parkinson’s disease
as well as worthwhile changes in the quality of their everyday
lives, including their daily activities, their emotional well being
and their cognitive and communication abilities,” said Herve
Lilliu, Head of Health Outcomes and Access, UCB.
The RECOVER trial was a multicenter, multinational,
double-blind, placebo-controlled study designed to assess the
effects of rotigotine in controlling early morning motor function
and non-motor symptoms that affect the everyday lives of people
with early- and late-stage Parkinson’s disease. Patients were
randomized (2:1) to receive rotigotine (2-16 mg/24 h) or placebo
during a titration period lasting up to 8 weeks, followed by a
4-week maintenance period.
PDQ-8 data were obtained from measurements taken at baseline and
at the end of the 12 week study from 89 placebo- and 176
rotigotine-randomized patients. Mean change from baseline PDQ-8
total score was greater in the rotigotine group (-6.9 [SD: 11.9])
than the placebo group (-1.2 [SD: 13.7]; p<0.001). Both the
rotigotine effect size (-0.41) and standardized response mean
(-0.58) were moderate based on the Cohen definition of change (0.20
sm
‘/>”/>